The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.

@article{Feuerbach2009TheSN,
  title={The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.},
  author={Dominik Feuerbach and Kurt Lingenhoehl and H. -R. Olpe and Annick Vassout and Conrad Gentsch and Fr{\'e}d{\'e}rique Chaperon and Joachim Nozulak and Albert Enz and Graeme Bilbe and Kevin McAllister and Daniel Hoyer},
  journal={Neuropharmacology},
  year={2009},
  volume={56 1},
  pages={254-63}
}
Several lines of evidence suggest that the nicotinic acetylcholine receptor alpha7 (nAChR alpha7) is involved in central nervous system disorders like schizophrenia and Alzheimer's disease as well as in inflammatory disorders like sepsis and pancreatitis. The present article describes the in vivo effects of JN403, a compound recently characterized to be a potent and selective partial nAChR alpha7 agonist. JN403 rapidly penetrates into the brain after i.v. and after p.o. administration in mice… CONTINUE READING
Highly Influential
This paper has highly influenced a number of papers. REVIEW HIGHLY INFLUENTIAL CITATIONS